Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer

OBJECTIVES: A drug that improves survival and/or disease progression can create real option value (ROV)—the additional health gain from future innovations enabled by a longer survival. ROV can be a relevant consideration for both clinical and payer decision-makers. We aimed to estimate the ex ante R...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Woojung, Wong, William B., Kowal, Stacey, Garrison, Louis P., Veenstra, David L., Li, Meng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130184/
https://www.ncbi.nlm.nih.gov/pubmed/35527331
http://dx.doi.org/10.1007/s40273-022-01147-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130184/
https://www.ncbi.nlm.nih.gov/pubmed/35527331
http://dx.doi.org/10.1007/s40273-022-01147-5

Ejemplares similares